The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study

Abstract Objectives The irreversible epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) afatinib and dacomitinib are approved for first-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and dacomi...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Wen-Chien Cheng, Chi-Chien Lin, Wei-Chih Liao, Yu-Chao Lin, Chia-Hung Chen, Hung-Jen Chen, Chih-Yen Tu, Te-Chun Hsia
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2024-02-01
סדרה:	BMC Cancer
נושאים:	Non-small cell lung cancer (NSCLC) Epidermal growth factor receptor (EGFR) Dacomitinib Afatinib
גישה מקוונת:	https://doi.org/10.1186/s12885-024-11956-w
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!